Evidence map›Paper›PMID 34296005›Full record

ArticleHeliyon2021

Doxorubicin induces dysregulation of AMPA receptor and impairs hippocampal synaptic plasticity leading to learning and memory deficits.

Ahmad H Alhowail, Priyanka D Pinky, Matthew Eggert, Jenna Bloemer, Lauren N Woodie, Manal A Buabeid, Subhrajit Bhattacharya, Shanese L Jasper, Dwipayan Bhattacharya, Muralikrishnan Dhanasekaran and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Heliyon, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Pathological α-Synuclein Perturbs Nuclear Integrity.bioRxiv : the preprint server for biology · 2025
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 7 institutions in 3 countries.

Ahmad H AlhowailDepartment of Pharmacology and Toxicology, Qassim University, Buraydah, Saudi Arabia.
Priyanka D PinkyDepartment of Drug Discovery and Development, Auburn University, Auburn, Alabama, USA.
Matthew EggertDepartment of Drug Discovery and Development, Auburn University, Auburn, Alabama, USA.
Jenna BloemerDepartment of Drug Discovery and Development, Auburn University, Auburn, Alabama, USA.
Lauren N WoodieDepartment of Nutrition, Dietetics and Hospitality Management, College of Human Sciences, Auburn University, Auburn, Alabama, USA.
Manal A BuabeidCollege of Pharmacy and Health Sciences, Ajman University, Ajman, United Arab Emirates.
Subhrajit BhattacharyaDepartment of Drug Discovery and Development, Auburn University, Auburn, Alabama, USA.
Shanese L JasperDepartment of Drug Discovery and Development, Auburn University, Auburn, Alabama, USA.
Dwipayan BhattacharyaDepartment of Pharmacology, Lake Erie College of Osteopathic Medicine, PA, USA.
Muralikrishnan DhanasekaranDepartment of Drug Discovery and Development, Auburn University, Auburn, Alabama, USA.
Martha EscobarDepartment of Psychology, Oakland University, Rochester, MI, USA.
Robert D ArnoldDepartment of Drug Discovery and Development, Auburn University, Auburn, Alabama, USA.
Vishnu SuppiramaniamDepartment of Drug Discovery and Development, Auburn University, Auburn, Alabama, USA.
Auburn University · USAjman University · AELake Erie College of Osteopathic Medicine · USOakland University · USQassim University · SATouro College · USUniversity of Pennsylvania · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Doxorubicin (Dox) is a chemotherapeutic agent used widely to treat a variety of malignant cancers. However, Dox chemotherapy is associated with several adverse effects, including "chemobrain," the observation that cancer patients exhibit through learning and memory difficulties extending even beyond treatment. This study investigated the effect of Dox treatment on learning and memory as well as hippocampal synaptic plasticity. Dox-treated mice (5 mg/kg weekly x 5) demonstrated impaired performance in the Y-maze spatial memory task and a significant reduction in hippocampal long-term potentiation. The deficit in synaptic plasticity was mirrored by deficits in the functionality of synaptic `α-amino-3- hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) channels, including reduced probability of opening, decreased dwell open time, and increased closed times. Furthermore, a reduction in the AMPAR subunit GluA1 level, its downstream signaling molecule Ca

Indexed as

AMPAChemobrainCognitive deficitsDoxorubicinLong-term potentiationSynaptic plasticity

Identifiers

PMID34296005
PMCPMC8282984
OpenAlexW3173976941

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.